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In 1997, Lo et al. demonstrated that fetal DNA circulates within the plasma and serum of pregnant women. This discovery was a breakthrough in the field of prenatal diagnosis and nowadays, non-invasive 
prenatal diagnosis is a reality but raises ethical, social and legal implications.  
 
Fetal DNA coexists with maternal DNA in the blood of pregnant women. Fetal DNA comes from apoptosis of trophoblasts due to the maternal immune system interaction. The test consists in 5-10 ml 
maternal blood sample extraction from which fetal DNA is isolated, to proceed with fetus genetic analysis and detect possible aneuploidy. Two results are possible: positive test or negative test; however, in 
any case, 100% reliability result can be obtained.  In addition, test allows fetal sex detection and Rh factor. This test allows the establishment of security and prevention measures during all pregnancy 
period. 
The aim of the project is the popularization of the non-invasive 
prenatal diagnosis by a leaflet to increase the level of 
knowledge about this technique, as well as, analyze the 
population knowledge and clinical application nowadays.  
 
The spreading of the technique has been performed by a leaflet that contains principal characteristics about the approximation; the 
information was obtained from NCBI (National Center for Biotechnology Information) searching articles in PubMed database.  
 
The leaflet has been distributed to 90 individuals. To analyze population knowledge, people have answered a short survey after they 
received the leaflet. Moreover, to analyze clinical application, I separated a subsample corresponding to pregnant women and recent 
mothers, who had to answer a few more questions about their pregnancy.  
Did you know this non invasive prenatal 
diagnosis technique before receiving the 
leaflet? 
Has the leaflet allowed you to understand 
what the technique is and which are main 
features? 
Non – invasive prenatal diagnosis vs. invasive prenatal diagnosis 
Invasive prenatal diagnosis 
Amniocentesis Chorionic  villus sample 
0.5-1% risk of miscarriage. 1-2% risk of miscarriage. 
It can be performed from 15 week of 
pregnancy. 
It can be performed between tenth and 
fourteenth week of pregnancy 
Obtaining of amniotic fluid by a tap in 
the abdomen. 
Obtaining chordal tissue vaginally. 
Reliable over 99% Reliable of 99% 
Results are obtained in 3 weeks. Results are obtained in 48-72 hours. 
THE TEST IS RECOMMENDED FOR: 
 
 Pregnant women over 35 years old. 
 Women who had a previous pregnancy with a 
child affected by an aneuploidy. 
 Carrier parents of a chromosome abnormality. 
 Fetal ultrasonographic findings indicating and 
increased risk of aneuploidy.  
Pre-test and post-test 
genetic counseling is 
essential to inform 
patients. 
• Free fetal DNA in maternal blood test is a safe approach, and is accurate and reliable, in the early detection of fetal autosomal and sexual                           
chromosome aneuploidy.   
• Analysis of free fetal DNA has advantages but it has got inconvenient too.  
• There are a lot of ethical, legal and social implications that have to be taken into account.  
• The leaflet has been a good method to approach non-invasive prenatal diagnosis to population. The level of knowledge about technique                                     
has been increased after people received the leaflet.  
• Most people have understood the leaflet and have been satisfied with design.  
• The test is offered to women to reject any fetal abnormalities and avoiding invasive tests, but not in all cases it’s carried out. 
• Less than half of women who performed the test receive genetic counseling. It should be provided in all cases.  
• The sample size corresponding to pregnant women is small. The study can be realize again with a bigger size sample.  
 
Average 
age: 37,46 
Average 
age of 
pregnancy:  
32,59 
Fetal DNA 
isolation 
Fetal DNA 
analysis 
Obtaining 
results  
Autosomal aneuploidy  
 21 Trisomy (Down Syndrome) 
 18 Trisomy (Edward Syndrome) 
 13 Trisomy (Patau Syndrome) 
Sexual chromosome aneuploidy  
 X Monosomy (Turner Syndrome) 
 XXY (Klinefelter Syndrome) 
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Non-invasive prenatal diagnosis 
Fetal free DNA in maternal blood 
There isn’t risk of miscarriage. There 
isn’t risk to the mother or fetus. 
It can be done from tenth week of 
pregnancy. 
Maternal blood sample extraction. 
Variability reliable 
Results can be obtained in 10 days. 
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Has this test been offered to 
you? 
Have you been offered  
genetic counseling? 
Have you executed this test to 
reject fetus alterations? 
100% of women had been 
informed about prenatal 
diagnosis approaches.  
5 
women 
6 
women 
Yes
No
18 
women 
9 
women 
 To reject  any fetal abnormality. 
 To avoid invasive test and abortion risk associated. 
 Presence of preliminary tests altered. 
 Positive family history for some abnormality. 
11 women 
7 women 
90 individuals 
62 women 
28 men 62 women 27 women 90 individuals 
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